Mycotoxins Test
A broad 29-marker urinary mycotoxin panel with quantitative LC-MS/MS methodology, published sample reporting, and useful reference-range documentation. Its biggest weaknesses are provider-mediated access, no confirmed public price, incomplete public validation detail, and the limited clinical meaning of a single urine result without exposure context.
Review status. This record is live for catalog testing, but its Test Grade and dimension scores are still awaiting editorial publication.
Mold exposure
The panel covers 29 mycotoxins across multiple toxin families.
Public patient pricing is not confirmed.